Solid Biosciences (SLDB)
(Real Time Quote from BATS)
$7.83 USD
-0.81 (-9.38%)
Updated Aug 2, 2024 03:02 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Solid Biosciences Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 8 | 14 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 8 | 14 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 104 | 115 | 86 | 88 | 119 |
Income After Depreciation & Amortization | -104 | -106 | -72 | -88 | -119 |
Non-Operating Income | 8 | 20 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -96 | -86 | -72 | -88 | -117 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -96 | -86 | -72 | -88 | -117 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -96 | -86 | -72 | -88 | -117 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -104 | -104 | -68 | -85 | -117 |
Depreciation & Amortization (Cash Flow) | 0 | 3 | 4 | 4 | 3 |
Income After Depreciation & Amortization | -104 | -106 | -72 | -88 | -119 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 19.88 | 8.51 | 7.12 | 3.46 | 2.69 |
Diluted EPS Before Non-Recurring Items | -4.83 | -10.10 | -10.20 | -24.89 | -43.63 |
Diluted Net EPS (GAAP) | -4.83 | -10.10 | -10.19 | -25.49 | -43.63 |
Fiscal Year end for Solid Biosciences Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 26.86 | 22.26 | 23.11 | 26.85 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -26.86 | -22.26 | -23.11 | -26.85 |
Non-Operating Income | NA | 2.65 | 1.93 | 2.13 | 2.21 |
Interest Expense | NA | 0.10 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -24.30 | -20.34 | -20.98 | -24.63 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -24.30 | -20.34 | -20.98 | -24.63 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -24.30 | -20.34 | -20.98 | -24.63 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.16 | 19.88 | 20.06 | 19.66 |
Diluted EPS Before Non-Recurring Items | NA | -0.64 | -1.00 | -1.05 | -1.25 |
Diluted Net EPS (GAAP) | NA | -0.64 | -0.99 | -1.05 | -1.25 |